17 results
8-K
EX-99.1
CRBU
Caribou Biosciences Inc
8 Jan 24
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
8:00am
, leading the company’s people strategy.
Expanded Caribou’s SAB with a renowned lymphoma expert and two leading multiple myeloma experts:
◦Stephen Schuster
S-1
EX-10.50
CRBU
Caribou Biosciences Inc
1 Jul 21
IPO registration
4:05pm
) information or records given or reports made to the Enterprise by an independent certified public accountant, an appraiser, investment banker or other expert
DEF 14A
CRBU
Caribou Biosciences Inc
11 Aug 22
Definitive proxy
4:04pm
is an independent director, qualifies as an “audit committee financial expert,” as defined under Item 407 of Regulation S-K. All audit services and all non-audit … Nasdaq rules and under Section 10A(m)(3) of the Exchange Act. The Company has identified Andrew Guggenhime as an “audit committee financial expert
S-1
EX-10.26
iuc9c
1 Jul 21
IPO registration
4:05pm
DRS
EX-10.23
gl1 dt07kf1
7 May 21
Draft registration statement
12:00am
8-K
EX-10.1
din5w56f
19 Jan 22
Entry into a Material Definitive Agreement
4:19pm
424B5
jkbmxis24n7utj l1ip9
13 Jul 23
Prospectus supplement for primary offering
4:56pm
424B5
75cdkmm6gsvdcdf6hzfg
14 Jul 23
Prospectus supplement for primary offering
5:31pm
S-1
kg0l n752
1 Jul 21
IPO registration
4:05pm
DRS
d5shf7onlx orzebk8r
7 May 21
Draft registration statement
12:00am
424B4
6rynr crpmubk
23 Jul 21
Prospectus supplement with pricing info
4:24pm
DRS/A
0cow6ok
11 Jun 21
Draft registration statement (amended)
12:00am
10-K
1onxe 9k240c
21 Mar 22
Annual report
4:19pm
S-1/A
srs2zx
19 Jul 21
IPO registration (amended)
6:09am
- Prev
- 1
- Next